Varenicline has proven effi cacy over bupropion SR for smoking abstinence in head-to-head clinical trials. Varenicline and bupropion SR produce 12-week (end-of-treatment) 7-day pointprevalent smoking abstinence rates of 50% and 36%, respectively, and are superior to placebo ( Gonzales et al., 2006 ; Jorenby et al., 2006 ) . However, relapse rates remain high. Among patients receiving 12 weeks of therapy with varenicline or bupropion SR, approximately two thirds and three quarters, respectively, report smoking at 6 months. Combinations of these medications may improve end-of-treatment smoking abstinence rates, which would translate into improved long-term outcomes.
Introduction
Varenicline and bupropion sustained release (SR) are nonnicotine pharmacotherapies indicated for the treatment of tobacco dependence in cigarette smokers. Varenicline is a partial agonist effecting partial receptor stimulation and competitive inhibition at the a 4 b 2 neuronal nicotinic acetylcholine receptors, which are proposed to mediate the reinforcing effects of nicotine ( Obach et al., 2006 ; Tapper et al., 2004 ) . Bupropion is proposed to work by blocking the reuptake of dopamine and norepinephrine in the reward centers of the central nervous system ( Ferris & Cooper, 1993 ) , which may simulate the reward achieved when smoking. Bupropion and its fi rst metabolite, hydroxybupropion, also may act as a nicotine antagonist at a 4 b 2 receptors ( Damaj et al., 2004 ; Slemmer, Martin, & Damaj, 2000 ) . Varenicline and bupropion SR are safe and effective aids to smoking cessation and have no known clinically signifi cant drug interactions. Croghan et al., 2007 ; Jorenby et al., 1999 ; Kornitzer, Boutsen, Dramaix, Thijs, & Gustavsson, 1995 ; Silagy, Lancaster, Stead, Mant, & Fowler, 2004 ). Combinations of medications in different therapeutic classes (i.e., nicotine replacement therapy and nonnicotine medication) also have been observed to increase smoking cessation rates compared with single-agent therapy ( Fiore et al., 2008 ) .
A new opportunity exists to combine varenicline and bupropion SR to capitalize on this potential additive benefi t and improve the treatment of tobacco dependence. We conducted an open-label, one-arm, Phase II clinical trial to obtain preliminary data on the effectiveness and safety of combination therapy with varenicline and bupropion SR for the treatment of tobacco dependence among cigarette smokers.
Methods Subjects
The Mayo Foundation Institutional Review Board reviewed and approved the study protocol prior to recruitment and enrollment. Individuals interested in stopping cigarette smoking were recruited through press releases and local advertisements from the community surrounding Mayo Clinic in Rochester, MN, between 10 September 2007 and 25 October 2007.
Subjects were eligible to participate if they were (a) at least 18 years of age, (b) smoking at least 10 cigarettes/day for at least 6 months, and (c) motivated to stop smoking. Subjects were excluded if they had (a) an unstable medical condition; (b) unstable angina, myocardial infarction, or coronary angioplasty within the previous 3 months or an untreated cardiac arrhythmia; (c) a history of seizures; (d) closed head trauma with any loss of consciousness or amnesia in the past 5 years; (e) a history of closed head trauma with at least 30 min of loss of consciousness or amnesia or resulting in skull fracture or subdural hematoma or brain contusion; (f) a history of psychosis, bipolar disorder, bulimia, or anorexia nervosa; (g) current depression as assessed by the Center for Epidemiological Studies Depression Scale (CES-D) ( Radloff, 1977 ) and clinician assessment; (h) active substance abuse other than nicotine; (i) used an investigational drug within the past 30 days; (j) current use of a behavioral or pharmacological tobacco treatment and unwilling or unable to discontinue use; (k) used bupropion or varenicline in the previous 30 days; (l) current (past 14 days) use of antipsychotics or antidepressants; (m) an allergy to bupropion or varenicline; (n) untreated hypertension or baseline systolic blood pressure of greater than 180 or diastolic blood pressure of greater than 100; or (o) another member of the household already participating in this study.
All female subjects of childbearing potential had to have a negative pregnancy test at least 7 days prior to study drug initiation and agree to use approved contraception during study participation.
Procedures
The study included a telephone screen and a total of 10 clinic visits: information meeting (screening and informed consent), baseline visit (screening and drug dispensing), seven biweekly medication phase visits, and an end-of-study visit at 6 months.
After initial screening by telephone, eligible subjects attended an information meeting during which details of the study were explained and informed consent was signed. Following completion of the informed consent, subjects completed screening questionnaires and interviews. After 1 week, subjects returned for a baseline visit during which they completed additional screening questionnaires and underwent a medical history and physical examination by a study physician.
In an open-label fashion, subjects received varenicline and bupropion SR, which were started simultaneously. Varenicline was titrated once daily (0.5-mg tablet) for 3 days, then 0.5 mg twice daily for Days 4 -7, and then to a 1.0-mg twice-daily maintenance dose for a total of 12 weeks. Bupropion SR was titrated one tablet by mouth (150 mg) once daily for Days 1 -3, then one tablet by mouth twice daily for a total of 12 weeks. The target quit date (TQD) was the eighth day of therapy.
Subjects returned biweekly for 12 weeks to receive medication and for assessment of medication adherence and adverse events. Brief behavioral counseling by a trained study assistant was completed at each study visit using the " Smoke Free and Living It " manual. The manual was designed to allow for an individualized intervention.
Assessments
At baseline, we assessed nicotine dependence with the Fagerström Test for Nicotine Dependence ( Heatherton, Kozlowski, Frecker, & Fagerström, 1991 ) and screened for depression with the CES-D Scale ( Radloff, 1977 ) . Readiness to quit smoking was assessed using the contemplation ladder ( Biener & Abrams, 1991 ) . Information on adverse events and concomitant medications was collected at each study visit.
Tobacco craving and nicotine withdrawal were assessed with a daily diary, which contained a tobacco use self-report and the Minnesota Nicotine Withdrawal Scale, Revised (MNWS-R; Hughes, 2007a Hughes, , 2007b . This measure consisted of the following nine items: desire or craving to smoke; anger, irritability, or frustration; anxiety or nervousness; diffi culty concentrating; impatience; restlessness; increased appetite or hunger; insomnia, sleep problems, or awakening at night; and depressed mood or sad. Based on the previous 24 hr, items were rated on a 5-point scale ranging from 0 (not present) to 4 (severe). This instrument is a reliable and valid measure of nicotine withdrawal ( Hughes et al., 2003 ) . Daily nicotine withdrawal data were obtained from the information session visit to 2 weeks after the TQD.
Compliance was assessed by conducting pill counts at each weekly visit and by self-reports about missed doses. Expired-air carbon monoxide (CO) measured in parts per million (ppm) was obtained at every visit with the Bedfont Micro III CO monitor. A level of 8 ppm or less was considered to verify selfreported smoking abstinence ( Benowitz et al., 2002 ) .
Smoking abstinence outcomes
The primary endpoints were the 7-day point-prevalent and prolonged smoking abstinence rates at the end of treatment (12 weeks). Secondary endpoints were the 7-day point-prevalent and prolonged smoking abstinence rates at 6 months ( Hughes et al., 2003 ) . Smoking abstinence outcomes were analyzed using an intention-to-treat approach that included an outcome for all enrolled subjects. Subjects reporting use of tobacco products other than cigarettes or with missing information were considered to be treatment failures.
Abstinence defi nitions were based on established criteria ( Hughes et al., 2003 ) . Point-prevalent smoking abstinence was adjudicated if the following two criteria were met: (a) self-reported smoking abstinence for the last 7 days as defi ned by a negative response to the question " Have you used any type of tobacco, even a puff, in the past 7 days? " and (b) expired CO ≤ 8 ppm. Prolonged smoking abstinence was adjudicated if criteria for 7-day pointprevalent smoking abstinence were satisfi ed and a negative response at each visit was obtained to the question " Since (month/ day/year), which was 2 weeks after your Target Quit Date, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks? " Consecutive weeks were counted starting from the TQD.
Data analyses
Subject characteristics were summarized with means, SD s, and ranges for continuous variables and percentages for categorical variables. Smoking abstinence rates at the end of treatment and 6 months were summarized using point estimates and 95% CI s. For each subject, the average withdrawal score on the MNWS-R for the 7 days prior to the baseline visit was used as the baseline score. Change from baseline (7 days prior to the start of medication) for the overall composite withdrawal score and for the individual symptom " desire to smoke " were summarized daily for the time period from start of medication to TQD and for the fi rst 2 weeks following TQD. To assess whether withdrawal symptoms changed signifi cantly from baseline, the one-sample t test was used to compare the mean change from baseline against zero. This Phase II trial was developed using a three-outcome design to assess whether the prolonged smoking abstinence rate at 12 weeks of treatment with varenicline and bupropion SR was at least 58% (clinically promising) versus 40% (consistent with the lower bound of the 95% CI for the abstinence rate observed in previous trials evaluating varenicline as monotherapy). Using the three-outcome study design, the primary endpoint was evaluated with a decision rule that could result in one of three possible conclusions: (a) the treatment is " ineffective, " (b) the treatment is " promising, " or (c) the result was " inconclusive " ( Sargent, Chan, & Goldberg, 2001 ). Based on the decision rule, we enrolled 38 subjects. If 17 or fewer subjects met criteria for prolonged smoking abstinence at the end of treatment, we would consider treatment " ineffective. " If 20 or more subjects were abstinent from smoking, we would consider treatment " clinically promising. " If 18 or 19 subjects were abstinent, the results would be considered " inconclusive. " Using this decision rule, if the true smoking abstinence rate was 58%, the probability (statistical power) of declaring the treatment " promising " was 0.799, the probability of declaring the treatment " ineffective " was 0.069, and the probability of an " inconclusive " fi nding was 0.132. If the true abstinence rate was 40%, the probability of declaring the treatment " promising " (Type I error) was 0.078, the probability of declaring the treatment " ineffective " was 0.778, and the probability of an inconclusive result was 0.144.
Results
A total of 38 cigarette smokers were enrolled in this pilot study ( Table 1 ) Most subjects had one or more previous quit attempts and were highly motivated to stop smoking. Five subjects (13%) withdrew consent and dropped out of the study.
Smoking abstinence
At the end of treatment, the 7-day point-prevalent smoking abstinence rate was 71% and the prolonged smoking abstinence rate was 63% ( Table 2 ) .
Nicotine withdrawal and tobacco craving
Among subjects taking varenicline and bupropion SR and still smoking prior to the TQD, we observed a signifi cant increase in the composite withdrawal ( Figure 1 ) . Following the TQD, the " desire to smoke " decreased signifi cantly compared with baseline by the sixth day among all subjects.
Weight change
At the end of treatment (Week 12), subjects meeting criteria for prolonged smoking abstinence gained a mean of 1.6 kg ( SD = 2.4) and a median of 1.4 kg (interquartile range [IQR] = -0.3 to 3.4]. At 6 months, subjects meeting criteria for prolonged smoking abstinence gained a mean of 4.2 kg ( SD = 3.5) and a median of 4.0 kg (IQR = 2.9 to 6.6).
Adverse events
The most common adverse events possibly, probably, or defi nitely associated with varenicline and bupropion SR were sleep disturbance (i.e., diffi culty initiating or maintaining sleep), nausea, insomnia, dizziness, vivid dreams (i.e., without disturbance of sleep initiation or maintenance), constipation, and dry mouth ( Table 3 ) . Two subjects (5%) rated the nausea and one subject (3%) rated dizziness as severe. No subjects dropped out of the study due to adverse events. All observed adverse events were anticipated as they had been described previously in association with varenicline or bupropion SR. No increase in depressive symptoms was observed, and no patients reported suicidal ideation.
Compliance
For both medications, 74% of subjects took at least 90% of prescribed doses as directed.
Discussion
The present study provides the fi rst evidence of the effectiveness and safety of combination therapy with varenicline and bupropion SR for smoking cessation. End-of-treatment and 6-month smoking abstinence rates were high. Medication adherence and the lack of dropouts due to adverse events enhance the clinical applicability of combination pharmacotherapy with these two agents.
Our data suggest a greater effect of combination therapy with varenicline and bupropion SR compared with either medication provided as monotherapy. We observed a 7-day pointprevalent smoking abstinence rate of 71% and a prolonged smoking abstinence rate of 63% at 12 weeks. In multicenter randomized, placebo-controlled clinical trials of varenicline ( Gonzales et al., 2006 ; Jorenby et al., 2006 ) , the 7-day pointprevalent smoking abstinence rate at 12 weeks was 50% and the continuous smoking abstinence rate for weeks 9 -12 was 44%. Compared with varenicline as monotherapy, the rate ratio of combination therapy for 7-day point-prevalent smoking abstinence at the end of treatment is approximately 1.4. At 6 months, we observed a 7-day point-prevalent smoking abstinence rate of 58% and a prolonged smoking abstinence of 53% with combination therapy. In multicenter trials, varenicline was observed to produce a 7-day point-prevalent smoking abstinence rate at 6 months of approximately 34% and a continuous abstinence rate for weeks 9 -24 of approximately 30% ( Gonzales et al., 2006 ; Jorenby et al., 2006 ) . Notably, subjects in the present study attended biweekly clinic visits with behavioral counseling, in contrast to the weekly clinic visits with behavioral counseling in these previous studies. Also, our endpoint defi nition of prolonged abstinence is more conservative than the continuous smoking abstinence endpoint of previous trials since our subjects had to report abstinence from smoking starting 2 weeks after the TQD to meet criteria. In a maintenance-of-abstinence study with varenicline, subjects received open-label varenicline for 12 weeks after which smoking-abstinent subjects were randomized in a blinded fashion to varenicline or placebo for an additional 12 weeks ( Tonstad et al., 2006 ) . In that study, the 7-day point-prevalent smoking abstinence rate was 64% at the end of the open-label phase (Week 12). Although abstinence rates are generally observed to be higher in open-label studies, subjects in the maintenance-of-abstinence study were required to be abstinent from smoking in the last week of the open-label phase to be randomized to the second phase, which may have increased smoking abstinence rates.
In addition to robust smoking abstinence rates, our preliminary study suggests that combination therapy with varenicline and bupropion SR results in signifi cant decreases in the " desire to smoke " (i.e., craving) but not in the composite withdrawal scores over the fi rst 2 weeks after the TQD. Signifi cant decreases in craving have been observed with both varenicline and bupropion SR as monotherapy compared with placebo ( Gonzales et al., 2006 ; Jorenby et al., 2006 ) . However, the effect of these drugs on subscale measures of nicotine withdrawal such as restlessness and increased appetite were either small or nonsignificant. Available experimental evidence has suggested that craving is associated with dopaminergic pathways, whereas withdrawal is attributed to nondopaminergic pathways ( Teneggi et al., 2002 ) . This experimental evidence may explain our observation that combination therapy, by sustaining dopaminergic tone (i.e., varenicline; Coe et al., 2005 ) or increasing dopaminergic tone by blocking dopamine reuptake (i.e., bupropion; Ferris & Cooper, 1993 ) , had more of an effect on tobacco craving than on nicotine withdrawal.
Varenicline as monotherapy does not have an effect on the attenuation of weight gain following smoking abstinence, but bupropion does ( Gonzales et al., 2006 ; Hays & Ebbert, 2003 ; Jorenby et al., 2006 ) . We observed that subjects meeting criteria for prolonged smoking abstinence in our study gained a mean of 1.6 kg during the medication phase. Our conservative prolonged abstinence defi nition (i.e., no smoking since 2 weeks after the TQD) had the potential to result in more weight gain than a less conservative defi nition (i.e., no smoking for the last 4 weeks of treatment), since patients could smoke for a longer period of time after the TQD and still meet criteria for a less conservative defi nition. However, we observed weight gain that was less than that observed with varenicline as monotherapy and comparable to that observed with bupropion SR in previous trials ( Hurt et al., 1997 ; Jorenby et al., 1999 Jorenby et al., , 2006 . The salutary effects of bupropion SR on weight gain associated with stopping smoking may provide additional rationale for combining it with varenicline.
The adverse events observed in this pilot study are similar to those observed in previous studies with both drugs. The most common reported adverse events were sleep disturbance (26%), nausea (24%), and insomnia (16%). The rates of reported insomnia and nausea are similar to those observed with bupropion SR and varenicline ( Gonzales et al., 2006 ; Jorenby et al., 2006 ) . In our study, 25 (66%) subjects reported at least one adverse event, which is similar to the percentage of subjects reporting any adverse event with varenicline and bupropion SR as monotherapy ( Gonzales et al., 2006 ) .
In addition to the small sample size, the major limitation of the present study is the open-label, one-sample design. We cannot exclude an effect of investigator and subject bias on study outcomes.
In summary, the present study provides preliminary evidence of the effectiveness and safety of combination pharmacotherapy with varenicline and bupropion SR for the treatment of tobacco dependence. Adequately powered, randomized, clinical trials assessing this medication would be a reasonable next step.
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